The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Photo of Mattias Ohlsson

Mattias Ohlsson

Professor

Photo of Mattias Ohlsson

The implementation of NILS : A web-based artificial neural network decision support tool for noninvasive lymph node staging in breast cancer

Author

  • Looket Dihge
  • Pär Ola Bendahl
  • Ida Skarping
  • Malin Hjärtström
  • Mattias Ohlsson
  • Lisa Rydén

Summary, in English

Objective: To implement artificial neural network (ANN) algorithms for noninvasive lymph node staging (NILS) to a decision support tool and facilitate the option to omit surgical axillary staging in breast cancer patients with low-risk of nodal metastasis. Methods: The NILS tool is a further development of an ANN prototype for the prediction of nodal status. Training and internal validation of the original algorithm included 15 clinical and tumor-related variables from a consecutive cohort of 800 breast cancer cases. The updated NILS tool included 10 top-ranked input variables from the original prototype. A workflow with four ANN pathways was additionally developed to allow different combinations of missing preoperative input values. Predictive performances were assessed by area under the receiver operating characteristics curves (AUC) and sensitivity/specificity values at defined cut-points. Clinical utility was presented by estimating possible sentinel lymph node biopsy (SLNB) reduction rates. The principles of user-centered design were applied to develop an interactive web-interface to predict the patient’s probability of healthy lymph nodes. A technical validation of the interface was performed using data from 100 test patients selected to cover all combinations of missing histopathological input values. Results: ANN algorithms for the prediction of nodal status have been implemented into the web-based NILS tool for personalized, noninvasive nodal staging in breast cancer. The estimated probability of healthy lymph nodes using the interface showed a complete concordance with estimations from the reference algorithm except in two cases that had been wrongly included (ineligible for the technical validation). NILS predictive performance to distinguish node-negative from node-positive disease, also with missing values, displayed AUC ranged from 0.718 (95% CI, 0.687-0.748) to 0.735 (95% CI, 0.704-0.764), with good calibration. Sensitivity 90% and specificity 34% were demonstrated. The potential to abstain from axillary surgery was observed in 26% of patients using the NILS tool, acknowledging a false negative rate of 10%, which is clinically accepted for the standard SLNB technique. Conclusions: The implementation of NILS into a web-interface are expected to provide the health care with decision support and facilitate preoperative identification of patients who could be good candidates to avoid unnecessary surgical axillary staging.

Department/s

  • Breast Cancer Surgery
  • LUCC: Lund University Cancer Centre
  • Personalized Breast Cancer Treatment
  • The Liquid Biopsy and Tumor Progression in Breast Cancer
  • Breast cancer prevention & intervention
  • Breast cancer treatment

Publishing year

2023

Language

English

Publication/Series

Frontiers in Oncology

Volume

13

Document type

Journal article

Publisher

Frontiers Media S. A.

Topic

  • Cancer and Oncology

Keywords

  • artificial intelligence
  • breast cancer
  • clinical decision support
  • disease diagnosis
  • lymphatic metastasis
  • neural networks
  • programmable calculator
  • sentinel lymph node

Status

Published

Research group

  • Breast Cancer Surgery
  • Personalized Breast Cancer Treatment
  • The Liquid Biopsy and Tumor Progression in Breast Cancer
  • Breast cancer prevention & intervention

ISBN/ISSN/Other

  • ISSN: 2234-943X